Table 2.
Comparison of pathologic parameters
| CHL, NS (N = 13) | PMLBCL (N = 16) | p value | Gray (N = 3) |
||
|---|---|---|---|---|---|
| Granuloma | Present or absent | 3(23.1%):10(76.9%) | 0:16(100%) | 0.078 | 0:3 |
| Fibrosis | Diffuse/nodular/reticular/none | 8(61.5%):5(38.5%):0:0 | 1(6.2%):1(6.2%):12(75.0%):2(12.5%) | < 0.001 | 1:2 |
| CD20 | Negative/focal/diffuse | 11(84.6%):2(13.4%):0 | 0:6(37.5%):10(62.5%) | < 0.001 | 0:3:0 |
| CD23 | Positive (> 30%) or negative | 1(8.3%):11(91.7%)a | 6(37.5%):10(62.5%) | 0.024 | 2:1 |
| CD30 | Diffuse/ focal/negative | 13(100%):0:0 | 6(37.5%):6(37.5%):4(25.0%) | 0.001 | 2:1 |
| IRF4/MUM1 | Positive (> 30%) or negative | 13(100%):0(0%) | 8(50.0%):8(50.0%) | 0.003 | 2:1 |
| BCL6 | Positive (> 30%) or negative | 0:12(100%)a | 9(56.2%):7(43.8%) | 0.003 | 1:2 |
| CD10 | Positive (> 30%) or negative | 0:12(100%)a | 1(6.3%):15(93.7%) | 1.000 | 0:3 |
| COO | GC or non-GCB | 0:12(100%)a | 6(37.5%):10(62.5%) | 0.024 | 0:3 |
| EBV | Present or absent | 1(7.7%):12(92.3%) | 1(6.2%):15(93.8%) | 1.000 | 0:3 |
| P63 | Positive (> 5%) or negative | 2(15.4%):11(84.6%) | 15(93.8%):1(6.2%) | < 0.001 | 2:1 |
| GATA3 | Positive (> 5%) or negative | 10(76.9%):3(23.1%) | 0:16(100%) | < 0.001 | 2:1 |
| CyclinE | Positive (> 5%) or negative | 0:13(100%) | 2(12.5%):14(87.5%) | 0.492 | 0:3 |
CHL classic Hodgkin lymphoma, NS nodular sclerosis, PMLBCL primary mediastinal diffuse large B-cell lymphoma (DLBCL); Gray, B-cell lymphoma unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma
a: immunohistochemistry for some antibodies was not done in one case due to exhaustion of stored tissues